Beijing Public Health Bureau Selects Sinovac To Supply Influenza Vaccine

Sinovac has reported that the Beijing Public Health Bureau has selected Sinovac to supply Anflu, Sinovac’s seasonal influenza vaccine. Developed and manufactured by Sinovac, Anflu is said to be a split influenza vaccine produced in China without preservatives.

The Beijing Public Health Bureau completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26, 2009. The agreement will be executed after the public notice period.

Sinovac recently has reported top-line preliminary results of H1N1 vaccine clinical trials. The results show the H1N1 vaccine developed by Sinovac is quite safe and has a good immunogenicity profile.

Weidong Yin, chairman, president and CEO of Sinovac, said: As part of our mission to develop vaccines to combat the spread of disease in China and around the world, we are pleased to again be among the seasonal flu suppliers to the Beijing government. We are confident of our flexibility to be able to fill large seasonal flu vaccine orders while also executing the R&D and large-scale production of our H1N1 vaccine.